- $4.25bn
- $2.58bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.38 | ||
| Price to Tang. Book | 1.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.51% | ||
| Return on Equity | -21.65% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Directors
- Carlos Paya NEC (62)
- Andrew Guggenhime PRE (51)
- Grant Pickering CEO (53)
- Jeff Fairman CFD (57)
- Jim Wassil COO (52)
- Paul Sauer SVP (59)
- Jane Wright-Mitchell CCO (52)
- Halley Gilbert DRC (51)
- Peter Hirth DRC
- Heath Lukatch DRC (53)
- Kurt Von Emster DRC (53)
- Annie Drapeau IND
- Michael Kamarck IND (70)
- Teri Loxam IND (49)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- November 27th, 2013
- Public Since
- June 12th, 2020
- No. of Shareholders
- 8
- No. of Employees
- 414
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 129,823,355
- Address
- 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, 94070
- Web
- https://vaxcyte.com/
- Phone
- +1 6508370111
- Auditors
- Deloitte & Touche LLP
Upcoming Events for PCVX
Similar to PCVX
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Vaxcyte share price?
As of Today at 23:54 UTC, shares in Vaxcyte are trading at $32.70. This share price information is delayed by 15 minutes.
How has the Vaxcyte share price performed this year?
Shares in Vaxcyte last closed at $32.70 and the price had moved by -58.31% over the past 365 days. In terms of relative price strength the Vaxcyte share price has underperformed the S&P500 Index by -64.1% over the past year.
What are the analyst and broker recommendations for Vaxcyte?
The overall consensus recommendation for Vaxcyte is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vaxcyte dividend yield?
Vaxcyte does not currently pay a dividend.
Does Vaxcyte pay a dividend?
Vaxcyte does not currently pay a dividend.
When does Vaxcyte next pay dividends?
Vaxcyte does not currently pay a dividend.
How do I buy Vaxcyte shares?
To buy shares in Vaxcyte you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vaxcyte?
As of the previous close price of $32.70, shares in Vaxcyte had a market capitalisation of $4.25bn.
Where are Vaxcyte shares listed?
Here are the trading details for Vaxcyte:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PCVX
What kind of share is Vaxcyte?
Based on an overall assessment of its quality, value and momentum Vaxcyte is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vaxcyte share price forecast for 2025?
The analyst consensus target price for shares in Vaxcyte is $114.88. That is 251.31% above the last closing price of $32.70.
Analysts covering Vaxcyte currently have a consensus Earnings Per Share (EPS) forecast of -$4.89 for the next financial year.
Find out moreWhat is the trend in the Vaxcyte share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaxcyte. Over the past six months, its share price has underperformed the S&P500 Index by -63%.
As of the last closing price of $32.70, shares in Vaxcyte were trading -46.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vaxcyte PE Ratio?
The Vaxcyte PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $32.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vaxcyte?
Vaxcyte's management team is headed by:
- Carlos Paya - NEC
- Andrew Guggenhime - PRE
- Grant Pickering - CEO
- Jeff Fairman - CFD
- Jim Wassil - COO
- Paul Sauer - SVP
- Jane Wright-Mitchell - CCO
- Halley Gilbert - DRC
- Peter Hirth - DRC
- Heath Lukatch - DRC
- Kurt Von Emster - DRC
- Annie Drapeau - IND
- Michael Kamarck - IND
- Teri Loxam - IND